465 related articles for article (PubMed ID: 25589763)
21. Amyloid precursor protein (APP) contributes to pathology in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis.
Bryson JB; Hobbs C; Parsons MJ; Bosch KD; Pandraud A; Walsh FS; Doherty P; Greensmith L
Hum Mol Genet; 2012 Sep; 21(17):3871-82. PubMed ID: 22678056
[TBL] [Abstract][Full Text] [Related]
22. Presymptomatic and symptomatic ALS SOD1(G93A) mice differ in adenosine A1 and A2A receptor-mediated tonic modulation of neuromuscular transmission.
Nascimento F; Sebastião AM; Ribeiro JA
Purinergic Signal; 2015 Dec; 11(4):471-80. PubMed ID: 26335190
[TBL] [Abstract][Full Text] [Related]
23. How to Build and to Protect the Neuromuscular Junction: The Role of the Glial Cell Line-Derived Neurotrophic Factor.
Stanga S; Boido M; Kienlen-Campard P
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33374485
[TBL] [Abstract][Full Text] [Related]
24. Muscle Expression of SOD1
Dobrowolny G; Martini M; Scicchitano BM; Romanello V; Boncompagni S; Nicoletti C; Pietrangelo L; De Panfilis S; Catizone A; Bouchè M; Sandri M; Rudolf R; Protasi F; Musarò A
Antioxid Redox Signal; 2018 Apr; 28(12):1105-1119. PubMed ID: 28931313
[TBL] [Abstract][Full Text] [Related]
25. Anti-disialosyl antibodies mediate selective neuronal or Schwann cell injury at mouse neuromuscular junctions.
Halstead SK; Morrison I; O'Hanlon GM; Humphreys PD; Goodfellow JA; Plomp JJ; Willison HJ
Glia; 2005 Nov; 52(3):177-89. PubMed ID: 15968629
[TBL] [Abstract][Full Text] [Related]
26. Analysis of neuromuscular junctions and effects of anabolic steroid administration in the SOD1G93A mouse model of ALS.
Cappello V; Vezzoli E; Righi M; Fossati M; Mariotti R; Crespi A; Patruno M; Bentivoglio M; Pietrini G; Francolini M
Mol Cell Neurosci; 2012 Aug; 51(1-2):12-21. PubMed ID: 22800606
[TBL] [Abstract][Full Text] [Related]
27. Altered terminal Schwann cell morphology precedes denervation in SOD1 mice.
Carrasco DI; Seburn KL; Pinter MJ
Exp Neurol; 2016 Jan; 275 Pt 1(0 1):172-81. PubMed ID: 26416261
[TBL] [Abstract][Full Text] [Related]
28. TDP-43 dysregulation and neuromuscular junction disruption in amyotrophic lateral sclerosis.
Lépine S; Castellanos-Montiel MJ; Durcan TM
Transl Neurodegener; 2022 Dec; 11(1):56. PubMed ID: 36575535
[TBL] [Abstract][Full Text] [Related]
29. Skeletal muscle-restricted expression of human SOD1 causes motor neuron degeneration in transgenic mice.
Wong M; Martin LJ
Hum Mol Genet; 2010 Jun; 19(11):2284-302. PubMed ID: 20223753
[TBL] [Abstract][Full Text] [Related]
30. Synapse-glia interactions at the mammalian neuromuscular junction.
Rochon D; Rousse I; Robitaille R
J Neurosci; 2001 Jun; 21(11):3819-29. PubMed ID: 11356870
[TBL] [Abstract][Full Text] [Related]
31. Temporospatial Analysis and New Players in the Immunology of Amyotrophic Lateral Sclerosis.
Iyer AK; Jones KJ; Sanders VM; Walker CL
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29473876
[TBL] [Abstract][Full Text] [Related]
32. Postsynaptic alteration of NR2A subunit and defective autophosphorylation of alphaCaMKII at threonine-286 contribute to abnormal plasticity and morphology of upper motor neurons in presymptomatic SOD1G93A mice, a murine model for amyotrophic lateral sclerosis.
Spalloni A; Origlia N; Sgobio C; Trabalza A; Nutini M; Berretta N; Bernardi G; Domenici L; Ammassari-Teule M; Longone P
Cereb Cortex; 2011 Apr; 21(4):796-805. PubMed ID: 20732897
[TBL] [Abstract][Full Text] [Related]
33. The expression of the chemorepellent Semaphorin 3A is selectively induced in terminal Schwann cells of a subset of neuromuscular synapses that display limited anatomical plasticity and enhanced vulnerability in motor neuron disease.
De Winter F; Vo T; Stam FJ; Wisman LA; Bär PR; Niclou SP; van Muiswinkel FL; Verhaagen J
Mol Cell Neurosci; 2006; 32(1-2):102-17. PubMed ID: 16677822
[TBL] [Abstract][Full Text] [Related]
34. Neuromuscular junction-on-a-chip: ALS disease modeling and read-out development in microfluidic devices.
de Jongh R; Spijkers XM; Pasteuning-Vuhman S; Vulto P; Pasterkamp RJ
J Neurochem; 2021 May; 157(3):393-412. PubMed ID: 33382092
[TBL] [Abstract][Full Text] [Related]
35. The role of glial cells in the formation and maintenance of the neuromuscular junction.
Feng Z; Ko CP
Ann N Y Acad Sci; 2008; 1132():19-28. PubMed ID: 18567850
[TBL] [Abstract][Full Text] [Related]
36. Dendrimer-2PMPA Delays Muscle Function Loss and Denervation in a Murine Model of Amyotrophic Lateral Sclerosis.
Tallon C; Sharma A; Zhang Z; Thomas AG; Ng J; Zhu X; Donoghue A; Schulte M; Joe TR; Kambhampati SP; Sharma R; Liaw K; Kannan S; Kannan RM; Slusher BS
Neurotherapeutics; 2022 Jan; 19(1):274-288. PubMed ID: 34984651
[TBL] [Abstract][Full Text] [Related]
37. GLT1 overexpression in SOD1(G93A) mouse cervical spinal cord does not preserve diaphragm function or extend disease.
Li K; Hala TJ; Seetharam S; Poulsen DJ; Wright MC; Lepore AC
Neurobiol Dis; 2015 Jun; 78():12-23. PubMed ID: 25818008
[TBL] [Abstract][Full Text] [Related]
38. Epothilone D accelerates disease progression in the SOD1
Clark JA; Blizzard CA; Breslin MC; Yeaman EJ; Lee KM; Chuckowree JA; Dickson TC
Neuropathol Appl Neurobiol; 2018 Oct; 44(6):590-605. PubMed ID: 29380402
[TBL] [Abstract][Full Text] [Related]
39. Neuromuscular Junction Dismantling in Amyotrophic Lateral Sclerosis.
Cappello V; Francolini M
Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 28972545
[TBL] [Abstract][Full Text] [Related]
40. Live imaging of amyotrophic lateral sclerosis pathogenesis: disease onset is characterized by marked induction of GFAP in Schwann cells.
Keller AF; Gravel M; Kriz J
Glia; 2009 Aug; 57(10):1130-42. PubMed ID: 19115383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
